相似文献
1
Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination - Kentucky, May-June 2021.
MMWR Morb Mortal Wkly Rep. 2021 Aug 13;70(32):1081-1083. doi: 10.15585/mmwr.mm7032e1.
2
The Incidence of SARS-CoV-2 Reinfection in Persons With Naturally Acquired Immunity With and Without Subsequent Receipt of a Single Dose of BNT162b2 Vaccine : A Retrospective Cohort Study.
Ann Intern Med. 2022 May;175(5):674-681. doi: 10.7326/M21-4130. Epub 2022 Feb 15.
3
Effectiveness Associated With Vaccination After COVID-19 Recovery in Preventing Reinfection.
JAMA Netw Open. 2022 Jul 1;5(7):e2223917. doi: 10.1001/jamanetworkopen.2022.23917.
4
Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study.
PLoS Med. 2022 Nov 22;19(11):e1004037. doi: 10.1371/journal.pmed.1004037. eCollection 2022 Nov.
5
COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis - California and New York, May-November 2021.
MMWR Morb Mortal Wkly Rep. 2022 Jan 28;71(4):125-131. doi: 10.15585/mmwr.mm7104e1.
6
SARS-CoV-2 Reinfection Rate and Estimated Effectiveness of the Inactivated Whole Virion Vaccine BBV152 Against Reinfection Among Health Care Workers in New Delhi, India.
JAMA Netw Open. 2022 Jan 4;5(1):e2142210. doi: 10.1001/jamanetworkopen.2021.42210.
7
SARS-CoV-2 Infections and Hospitalizations Among Persons Aged ≥16 Years, by Vaccination Status - Los Angeles County, California, May 1-July 25, 2021.
MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1170-1176. doi: 10.15585/mmwr.mm7034e5.
8
SARS-CoV-2 immune response and reinfection in vaccinated Maya and mestizo in Southeast of Mexico.
Salud Publica Mex. 2023 Dec 8;66(1, ene-feb):14-16. doi: 10.21149/15186.
9
Epidemiological assessment of SARS-CoV-2 reinfection.
Int J Infect Dis. 2022 Oct;123:9-16. doi: 10.1016/j.ijid.2022.07.075. Epub 2022 Aug 2.
10
Breakthrough SARS-CoV-2 infections after vaccination: a critical review.
Hum Vaccin Immunother. 2022 Nov 30;18(5):2051412. doi: 10.1080/21645515.2022.2051412. Epub 2022 Mar 18.
引用本文的文献
1
Changes in peripheral blood mononuclear cell electrical properties in response to viral exposure and vaccination.
Sci Rep. 2025 Jul 9;15(1):24583. doi: 10.1038/s41598-025-08724-6.
2
Viral dynamics and factors associated with duration of COVID-19 positivity: evidence from the first-three epidemiological waves in Cameroon.
BMC Infect Dis. 2025 May 5;25(1):660. doi: 10.1186/s12879-025-11048-5.
3
Role of COVID-19 infection status on the prediction of future infection: Immunity or susceptibility.
PLoS One. 2025 Mar 26;20(3):e0317959. doi: 10.1371/journal.pone.0317959. eCollection 2025.
4
Protection afforded by post-infection SARS-CoV-2 vaccine doses: A cohort study in Shanghai.
Elife. 2025 Feb 17;13:RP94990. doi: 10.7554/eLife.94990.
5
COVID-19 vaccine uptake in a predominantly minoritized cohort hospitalized during the early pandemic in New York City.
Vaccine. 2024 Dec 2;42(26):126260. doi: 10.1016/j.vaccine.2024.126260. Epub 2024 Sep 11.
6
Association of Prior COVID-19 Infection with Risk of Breakthrough Infection Following Vaccination: A Cohort Study in Isfahan, Iran.
Int J Prev Med. 2024 Jul 17;15:18. doi: 10.4103/ijpvm.ijpvm_173_23. eCollection 2024.
7
Physiological Response to the COVID-19 Vaccine: Insights From a Prospective, Randomized, Single-Blinded, Crossover Trial.
J Med Internet Res. 2024 Jul 31;26:e51120. doi: 10.2196/51120.
8
Quantifying Disparities in COVID-19 Vaccination Rates by Rural and Urban Areas: Cross-Sectional Observational Study.
JMIR Public Health Surveill. 2024 Jul 19;10:e50595. doi: 10.2196/50595.
9
Barriers to initial COVID-19 booster among US adults who completed a primary vaccine series in the CHASING COVID cohort, September 2021-October 2022.
Am J Epidemiol. 2025 May 7;194(5):1341-1351. doi: 10.1093/aje/kwae209.
10
COVID-19 Booster Vaccination Status and Long COVID in the United States: A Nationally Representative Cross-Sectional Study.
Vaccines (Basel). 2024 Jun 20;12(6):688. doi: 10.3390/vaccines12060688.
本文引用的文献
1
Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant.
Cell. 2021 Jun 24;184(13):3426-3437.e8. doi: 10.1016/j.cell.2021.04.025. Epub 2021 Apr 20.
2
mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection.
Science. 2021 Mar 25;372(6549):1413-8. doi: 10.1126/science.abg9175.
3
Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2.
JAMA. 2021 Apr 13;325(14):1467-1469. doi: 10.1001/jama.2021.3341.
4
Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals.
Lancet. 2021 Mar 20;397(10279):1057-1058. doi: 10.1016/S0140-6736(21)00501-8. Epub 2021 Feb 25.
5
Potential SARS-CoV-2 Immune Correlates of Protection in Infection and Vaccine Immunization.
Pathogens. 2021 Jan 30;10(2):138. doi: 10.3390/pathogens10020138.
6
SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis.
Lancet Microbe. 2021 Jan;2(1):e13-e22. doi: 10.1016/S2666-5247(20)30172-5. Epub 2020 Nov 19.
7
Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support.
J Biomed Inform. 2009 Apr;42(2):377-81. doi: 10.1016/j.jbi.2008.08.010. Epub 2008 Sep 30.
Zotero 插件